GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, announced terms for its IPO on Tuesday. The Louisville, CO-based company plans to raise $35 million by offering 2.2 million shares at a price range of $15 to $17. At the midpoint of the proposed range, it would command a fully diluted market value of $94 million. The company previously tried to raise $60 million at a proposed market value of $207 million but postponed its IPO in October 2012 and withdrew in October 2013.
GlobeImmune, which was founded in 1995 and booked $22 million in collaboration revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol GBIM. Aegis Capital is the sole bookrunner on the deal.
